Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients
about
Third-Generation Tyrosine Kinase Inhibitors Targeting Epidermal Growth Factor Receptor Mutations in Non-Small Cell Lung CancerResistance to epidermal growth factor receptor tyrosine kinase inhibitors, T790M, and clinical trials.Analyzing EGFR mutations and their association with clinicopathological characteristics and prognosis of patients with lung adenocarcinoma.Afatinib in advanced pretreated non-small-cell lung cancer— a Canadian experience
P2860
Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Clinical impact of mutation fr ...... tation positive NSCLC patients
@ast
Clinical impact of mutation fr ...... tation positive NSCLC patients
@en
type
label
Clinical impact of mutation fr ...... tation positive NSCLC patients
@ast
Clinical impact of mutation fr ...... tation positive NSCLC patients
@en
prefLabel
Clinical impact of mutation fr ...... tation positive NSCLC patients
@ast
Clinical impact of mutation fr ...... tation positive NSCLC patients
@en
P2093
P2860
P356
P1476
Clinical impact of mutation fr ...... tation positive NSCLC patients
@en
P2093
Anthea Lau
Brian Higgins
Carolyn J Shiau
David Hwang
Frances A Shepherd
Maria Pasic
Matilda Ng
Natasha B Leighl
P2860
P2888
P304
P356
10.1038/BJC.2016.22
P407
P577
2016-02-18T00:00:00Z